Collegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue

MT Newswires Live09-04

Collegium Pharmaceutical (COLL) said Wednesday that it has completed its $525 million, all-cash acquisition of Ironshore Therapeutics, which markets and distributes the Jornay PM drug treatment for attention deficit hyperactivity disorder.

Collegium said it now expects to generate between $620 million to $635 million in product revenue this year, up from its prior forecast of $580 million to $595 million.

The company also said it now expects 2024 adjusted earnings before interest, taxes, depreciation and amortization of $395 million to $405 million, up from $380 million to $395 million anticipated previously.

Price: 37.42, Change: -0.01, Percent Change: -0.01

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464305406?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-04 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2464305406","market":"nz","top_or_hot":-1,"title":"Collegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue","media":"MT Newswires Live","content":"<html><body><p> Collegium Pharmaceutical (COLL) said Wednesday that it has completed its $525 million, all-cash acquisition of Ironshore <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, which markets and distributes the Jornay PM drug treatment for attention deficit hyperactivity disorder.</p><p>Collegium said it now expects to generate between $620 million to $635 million in product revenue this year, up from its prior forecast of $580 million to $595 million.</p><p>The company also said it now expects 2024 adjusted earnings before interest, taxes, depreciation and amortization of $395 million to $405 million, up from $380 million to $395 million anticipated previously.</p><p>Price: 37.42, Change: -0.01, Percent Change: -0.01</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-04 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Collegium Pharmaceutical (COLL) said Wednesday that it has completed its $525 million, all-cash acquisition of Ironshore Therapeutics, which markets and distributes the Jornay PM drug treatment for ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COLL","symbol_name":"Collegium Pharmaceutical, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2464305406","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464305406","pubTimestamp":1725458382,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Collegium Pharmaceutical  said Wednesday that it has completed its $525 million, all-cash acquisition of Ironshore Therapeutics, which markets and distributes the Jornay PM drug treatment for attention deficit hyperactivity disorder.Collegium said it now expects to generate between $620 million to $635 million in product revenue this year, up from its prior forecast of $580 million to $595 million.The company also said it now expects 2024 adjusted earnings before interest, taxes, depreciation and amortization of $395 million to $405 million, up from $380 million to $395 million anticipated previously.Price: 37.42, Change: -0.01, Percent Change: -0.01","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"COLL":"Collegium Pharmaceutical, Inc.","LENZ":"Therapeutics"},"translate_title":"Collegium完成对Ironshore Therapeutics的收购；提高2024年产品收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"COLL":0.9},"content_text":"Collegium Pharmaceutical (COLL) said Wednesday that it has completed its $525 million, all-cash acquisition of Ironshore Therapeutics, which markets and distributes the Jornay PM drug treatment for attention deficit hyperactivity disorder.Collegium said it now expects to generate between $620 million to $635 million in product revenue this year, up from its prior forecast of $580 million to $595 million.The company also said it now expects 2024 adjusted earnings before interest, taxes, depreciation and amortization of $395 million to $405 million, up from $380 million to $395 million anticipated previously.Price: 37.42, Change: -0.01, Percent Change: -0.01","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464305406"}